Cargando…
Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib
Lung carcinoma is the leading cause of death by cancer in the world. Nowadays, most patients will experience disease progression during or after first-line chemotherapy demonstrating the need for new, effective second-line treatments. The only approved second-line therapies for patients without targ...
Autores principales: | Corrales, Luis, Nogueira, Amanda, Passiglia, Francesco, Listi, Angela, Caglevic, Christian, Giallombardo, Marco, Raez, Luis, Santos, Edgardo, Rolfo, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329017/ https://www.ncbi.nlm.nih.gov/pubmed/28293555 http://dx.doi.org/10.3389/fmed.2017.00013 |
Ejemplares similares
-
Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…
por: Thungappa, Satheesh, et al.
Publicado: (2017) -
Challenges in Lung Cancer Screening in Latin America
por: Raez, Luis E., et al.
Publicado: (2018) -
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
por: Passiglia, Francesco, et al.
Publicado: (2016) -
Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015
por: Rolfo, Christian, et al.
Publicado: (2016) -
Neuregulin 1 Gene (NRG1). A Potentially New Targetable Alteration for the Treatment of Lung Cancer
por: Rosas, Daniel, et al.
Publicado: (2021)